The FDA approved Lenacapavir, the first twice-a-year injection to prevent HIV, marking a historic step in public health.

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The US FDA has approved lenacapvir, sold under the brand name Yeztugo, as the first preventive treatment against HIV. It is a ...

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

A newly approved HIV medication provides near-total protection against infection with just two injections a year. It's called Lenacapavir. But the high price of the drug could limit its reach.

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year ...

Gilead tested lenacapavir—which was approved by the FDA in 2022 as a treatment for patients with drug-resistant HIV—in two clinical trials against its daily prophylactic pills.